Singapore Principal Investigators Bring Innovative Precision Medicine Methods to Global Glioblastoma Clinical Trial

Singapore Principal Investigators Bring Innovative Precision Medicine Methods to Global Glioblastoma Clinical Trial

A $10 million national grant from Singapore supports a global research collaborative effort targeting the challenges associated with glioblastoma, a highly aggressive and deadly type of brain cancer, to develop new diagnostic and treatment options so patients can receive effective targeted therapy. Led by investigators at the National Neuroscience Institute (NNI), National University of Singapore (NUS), and Duke-NUS Medical School (Duke-NUS), the team recently received a research grant under what’s known as the Open Fund Large Collaborative Grant.  (MOH-000541) from the National Research Foundation Singapore, administered by the Singapore Ministry of Health’s National Medical Research Council. This program involves four themes, involving first and foremost the creation of original tumor models for improving research and drug testing followed by the acceleration of knowledge gains via AI-based drug discovery, leveraging the UK’s BenevolentAI. The team then plans on actually bringing the results of this precision methodology into clinical practice while participating in global adaptive clinical trials. Researchers and sponsors tracking glioblastoma should follow this study carefully...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee